^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    evofosfamide (IMGS-101)

    i
    Company:
    ImmunoGenesis
    Drug class:
    Alkylating agent
    Related drugs:
    Apply
    Immunotherapy Study of Evofosfamide in Combination With Ipilimumab (NCT03098160)
    Phase 1
    Threshold Pharmaceuticals
    Unknown status
    Last update posted :
    10/30/2017
    Initiation :
    05/10/2017
    Primary completion :
    01/01/2019
    Completion :
    04/01/2019
    PD-L1 • IL2
    |
    Yervoy (ipilimumab) • evofosfamide (IMGS-101)